Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

140.78 -1.66 (-1.16%)

Streaming Delayed Price Updated: 10:13 AM EDT, Sep 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗

March 21, 2026

This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.

Via The Motley Fool

Topics Regulatory Compliance

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗

March 21, 2026

Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.

Via The Motley Fool

Topics Regulatory Compliance

This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗

March 20, 2026

RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.

Via The Motley Fool

Topics Regulatory Compliance

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In ↗

October 14, 2025

Via Stocktwits

Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis

March 18, 2026

Via ACCESS Newswire

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

March 02, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026

Via ACCESS Newswire

Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

February 25, 2026

Via ACCESS Newswire

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

Via The Motley Fool

Topics Regulatory Compliance

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in March 2026

February 24, 2026

Via ACCESS Newswire

Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance ↗

February 16, 2026

This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.

Via The Motley Fool

Topics Regulatory Compliance

Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes ↗

February 01, 2026

The chief medical officer at one of the top pharmaceutical companies sold nearly 10,000 shares in late January 2026, but the reason was for something very simple.

Via The Motley Fool

Topics Regulatory Compliance

"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape

January 15, 2026

As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026

January 07, 2026

Via ACCESS Newswire

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

January 05, 2026

From Takeda Pharmaceutical Company Limited

Via Business Wire

Protagonist (PTGX) Earnings Call Transcript ↗

November 27, 2025

Protagonist (PTGX) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

November 27, 2025

Via ACCESS Newswire

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 06, 2025

Via ACCESS Newswire

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

November 03, 2025

Via ACCESS Newswire

What 7 Analyst Ratings Have To Say About Protagonist Therapeutics ↗

October 28, 2025

Via Benzinga

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

October 27, 2025

Via ACCESS Newswire

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million ↗

October 23, 2025

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million

Via The Motley Fool

Topics Energy

Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million ↗

October 23, 2025

Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million

Via The Motley Fool

Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million ↗

October 21, 2025

Moody Aldrich Liquidates Entire Stake in PLMR Worth $8.2 Million

Via The Motley Fool

Topics Regulatory Compliance

Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?

October 20, 2025

Via AB Newswire

2 Top Dividend Kings Every Income Investor Should Own ↗

October 20, 2025

These companies pay durable and steadily rising dividends.

Via The Motley Fool

Topics Bonds

Johnson & Johnson's M&A Strategy Is the Real Story for Investors ↗

October 18, 2025

Johnson & Johnson’s rumored Protagonist buyout demonstrates its proven M&A strategy: divesting low-growth units to fund high-margin, innovative assets.

Via MarketBeat

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗

October 14, 2025

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.

Via Benzinga

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print ↗

October 14, 2025

Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline.

Via Stocktwits

Topics Government World Trade

Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch ↗

October 13, 2025

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.